The Effect of Sodium Monofluorophosphate Plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. A Randomized, Controlled Trial
The Effect of Sodium Monofluorophosphate Plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. A Randomized, Controlled Trial.pdf
[en] BACKGROUND: Fluoride is effective in increasing trabecular bone mineral density (BMD) in the spine, but its efficacy in reducing vertebral fracture rates and its effect on BMD at cortical sites are controversial. OBJECTIVE: To study the effect of low-dose fluoride (sodium monofluorophosphate [MFP]) plus a calcium supplement over 4 years on vertebral fractures and BMD at the lumbar spine and total hip in postmenopausal women with moderately low BMD of the spine. DESIGN: Randomized, double-blind, controlled clinical trial. SETTING: Outpatient clinic for osteoporosis at a university medical center. PATIENTS: 200 postmenopausal women with osteoporosis (according to the World Health Organization definition) and a T-score less than -2.5 for BMD of the spine. INTERVENTION: Women were randomly assigned (100 patients per group) to continuous daily treatment for 4 years with 1) oral MFP (20 mg of equivalent fluoride) plus 1000 mg of calcium (as calcium carbonate) or 2) calcium only. MEASUREMENTS: Lateral spine radiographs were taken at enrollment and at each year of follow-up for detection of new vertebral fractures (defined as a reduction > or =20% and > or =4 mm from baseline in any of the heights of a vertebral body). Nonvertebral fractures were also recorded. All analyses were done with the intention-to-treat approach. RESULTS: Radiologic follow-up was possible for 164 of 200 patients (82%). The rate of new vertebral fractures during the 4 years of the study was lower in the MFP-plus-calcium group (2 of 84 patients; 2.4% [95% CI, 0.3% to 8.3%]) than in the calcium-only group (8 of 80 patients; 10% [CI, 4.4% to 18.8%]). The difference between the groups was 7.6 percentage points (CI, 0.3 to 15 percentage points) (P = 0.05). A moderate but progressive increase in BMD of the spine (10.0% +/- 1.5% at 4 years) was found for MFP plus calcium compared with calcium only (P < 0.001), whereas the more modest increase in BMD of the total hip seen with MFP plus calcium (1.8% +/- 0.6%) did not differ from the increase seen with calcium only. CONCLUSIONS: Low-dose fluoride (20 mg/d) given continuously with calcium for prolonged periods can decrease vertebral fracture rates compared with calcium alone in patients with mild to moderate osteoporosis.
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Meurmans, L.
Zegels, Brigitte ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Rovati, L. C.
Minne, H. W.
Giacovelli, G.
Taquet, A. N.
Setnikar, I.
Collette, Julien ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Gosset, Christiane ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique : aspects généraux
Language :
English
Title :
The Effect of Sodium Monofluorophosphate Plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. A Randomized, Controlled Trial
Publication date :
01 July 1998
Journal title :
Annals of Internal Medicine
ISSN :
0003-4819
eISSN :
1539-3704
Publisher :
American College of Physicians, United States - Pennsylvania
Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science. 1983; 222:330-2.
Reed BY, Zerwekh JE, Antich PP, Pak CY. Fluoride-stimulated 913H 93thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor β. J Bone Miner Res. 1993;8:19-25.
Kanis JA. Treatment of symptomatic osteoporosis with fluoride. Am J Med. 1993;95:S53-S61.
Heaney RP, Baylink DJ, Johnston CC Jr, Melton LJ 3d, Meunier PJ, Murray TM, et al. Fluoride therapy for the vertebral crush fracture syndrome. A status report. Ann Intern Med. 1989;111:678-80.
Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322:802-9.
Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med. 1995;123:401-8.
Mamelle N, Meunier PJ, Dusan R, Guillaume M, Martin JL, Gaucher A, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet. 1988;2:361-5.
Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom P, Netter G, et al. Fluoride salts are no better prevention at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOS study. Osteoporosis Int. 1998;8:4-12.
Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int. 1991;1:155-61.
Riggs BL, Wahner HW, Dunn WL, Mazess RB, Oxford KP, Melton LJ 3d. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981; 67:328-35.
Reginster JY, Janssen C, Deroisy R, Zegels B, Albert A, Franchimont P. Bone mineral density of the spine and the hip measured with dual energy x-ray absorptiometry: normal range and fracture threshold for western European (Belgian) postmenopausal females. Clin Rheum. 1995;14:68-75.
Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Report of a World Health Organization Study Group. Geneva: World Health Organization; 1994.
Reginster JY, Compston JE, Jones EA, Kaufman JM, Audran M, Bouvenot G, et al. Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis [Editorial]. Calcif Tissue Int. 1995;57:247-50.
Melton LJ 3d, Kan SH, Frye KM, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129: 1000-11.
Minne HW, Leidig G, Wuster C, Siromachkostov L, Baldauf G, Bickel R, et al. A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis. Bone Miner. 1988;3:335-49.
Stein JA, Lazewatski JL, Hochberg AM. Dual-energy x-ray bone densitometer incorporating an internal reference system [Abstract]. Radiology. 1987; 165P:313.
Riggs BL, O'Fallon W, Hodgson S, Chao E, Wahner H, Muhs J, et al. Clinical trial of fluoride in osteoporotic women: extended observation and additional analyses [Abstract], Bone Miner. 1992;17:S74.
Parfitt AM. Bone remodelling: relationship to the amount and structure of bone and the pathogenesis and prevention of fractures. In: Riggs BL, Melton LJ 3d, eds. Osteoporosis: Etiology, Diagnosis, and Management. New York: Raven; 1988:45-93.
Delmas PD, Dupuis J, Duboeuf F, Chapuy MC, Meunier PJ. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride. J Bone Miner Res. 1990;5(Suppl):S143-7.
Ericsson Y. Monofluorophosphate physiology: general considerations. Caries Res. 1983; 17:S46-S55.
Muller P, Schmid K, Warnecke G, Setnikar I, Simon B. Sodium fluoride-induced gastric mucosal lesions: comparison with sodium monofluorophosphate. Z Gastroenterol. 1992;30:252-4.
Warneke G, Setnikar I. Effects of meal on the pharmacokinetics of fluoride from oral monofluorophosphate. Arzneimittelforschung. 1993;43:592-5.